Your Health, We Care
Another NameGomekli、Ezmekly、莫达美替尼
IndicationsA therapy for the treatment of adult and pediatric patients aged 2 years and older with NF1-PN.
Reg No.03-LM-01455-26
Inspection NO.447-26
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Mirdametinib is a prescription drug targeting MEK1 and MEK2, and it must be used strictly in accordance with doctors' instructions.
MEK1, MEK2
Route and frequency of administration of Mirdametinib: Oral, twice daily.
The dosage of Mirdametinib should be adjusted according to the patient's actual condition. Please consult your physician for specific instructions and follow medical advice.
Recommended reading: Dosage and Administration of Mirdametinib
Common side effects: Diarrhea, nausea, muscle, joint, and bone pain, etc.
Serious side effects: Eye problems, blurred vision, vision loss, etc.
Pregnancy: Before you start treatment with Mirdametinib, your healthcare provider should check whether you are pregnant. During treatment with Mirdametinib and for 6 weeks after the last dose, please take effective contraceptive measures.
Breastfeeding: It is not known whether Mirdametinib passes into breast milk. Do not breastfeed during treatment with Mirdametinib and for 1 week after the last dose.
1. Inform patients and caregivers that Mirdametinib may cause serious ocular adverse reactions; if any vision changes occur, contact a healthcare provider immediately.
2. Inform patients and caregivers that Mirdametinib may cause a decrease in left ventricular ejection fraction (LVEF); if any signs or symptoms of left ventricular dysfunction occur, notify a healthcare provider immediately.
3. Inform patients and caregivers that Mirdametinib can cause severe skin adverse reactions; if skin discomfort occurs, contact a healthcare provider promptly; additionally, this medication may cause hair loss.
FDA，2025.11
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
